Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
73%
Erlotinib
46%
Neoplasm
41%
Lung Cancer
34%
Malignant Neoplasm
30%
Gefitinib
29%
Chemotherapy
27%
Epidermal Growth Factor Receptor Kinase Inhibitor
17%
Afatinib
14%
Pharmacokinetics
14%
Tumor Microenvironment
13%
Active Metabolite
13%
Biological Marker
13%
Stomach Cancer
13%
Immune Checkpoint Inhibitor
12%
Adverse Event
12%
Protein Tyrosine Kinase Inhibitor
11%
Lung Adenocarcinoma
11%
CD8 Antigen
11%
Central Nervous System Metastasis
10%
Epidermal Growth Factor
10%
Disease Exacerbation
10%
Progression Free Survival
9%
Interstitial Lung Disease
9%
Cisplatin
8%
Small Cell Lung Cancer
8%
Anaplastic Lymphoma Kinase
8%
Anaplastic Lymphoma Kinase Inhibitor
8%
Mitogen Activated Protein Kinase Kinase Inhibitor
8%
Hemodialysis
8%
Squamous Cell Lung Carcinoma
8%
Adenocarcinoma
7%
Combination Therapy
6%
Nivolumab
6%
Lapatinib
6%
Metastatic Colorectal Cancer
6%
C Reactive Protein
5%
Overall Survival
5%
Scatter Factor
5%
Disease
5%
Recurrent Disease
5%
Pembrolizumab
5%
Primary Tumor
5%
Phosphotransferase
5%
Medicine and Dentistry
Epidermal Growth Factor Receptor
57%
Neoplasm
45%
Non Small Cell Lung Cancer
33%
Lung Cancer
33%
Tumor Microenvironment
26%
T Cell
18%
Cytotoxic T-Cell
17%
Malignant Neoplasm
17%
Gefitinib
17%
Lung Adenocarcinoma
15%
Cell Line
14%
Immune Checkpoint Inhibitor
14%
Receptor Gene
14%
Regulatory T Cell
13%
Afatinib
13%
Chemoradiotherapy
13%
Stomach Cancer
13%
Clinical Significance
13%
Primary Tumor
12%
Tumor Infiltrating Lymphocyte
12%
Major Histocompatibility Complex
11%
Gene Mutation
10%
Tumor Cell
9%
Nivolumab
8%
Loeys-Dietz Syndrome
8%
Epidermal Growth Factor
8%
Rectum Cancer
8%
Progression Free Survival
8%
Radiation Therapy
7%
Smoking
7%
Somatic Mutation
7%
Programmed Death-Ligand 1
7%
Metastatic Carcinoma
6%
Erlotinib
6%
Immunotherapy
6%
Overall Survival
6%
Cellular Infiltration
6%
Receptor
5%
C Reactive Protein
5%
Combination Therapy
5%
Tyrosine-Kinase Inhibitor
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Tumor Immune Microenvironment
5%
Microsatellite Instability
5%
Upregulation
5%
Immunosuppressive Treatment
5%
Nodular Melanoma
5%
Monoclonal Antibody
5%
Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
25%
Erlotinib
22%
Gefitinib
20%
Non-small Cell Lung Cancer (NSCLC)
16%
Clinical Significance
13%
EGFR mutation
12%
Japanese Patients
11%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
10%
Non-squamous Non-small Cell Lung Cancer
9%
Epidermal Growth Factor Receptor
8%
Interstitial Lung Disease
8%
Insulin-like
8%
Small Cell Lung Cancer
8%
Clinical Specimens
8%
Binding Protein
8%
Cerebrospinal Fluid Concentration
8%
Growth Factors
7%
Cancer Immunotherapy
7%
Tumor Microenvironment
6%
CNS Metastases
6%
S768I
6%
Chemotherapy
5%
Wild-type Epidermal Growth Factor Receptor
5%
OSI-420
5%
Tumor Immunity
5%
Somatic mutation
5%
Phase II Study
5%
Leptomeningeal Metastasis
5%
CD8+ T Cells
5%
Growth-related Genes
5%